First–in–class capsid inhibitor that targets HIV–1 at multiple stages of the HIV–1 lifecycle1,3. The capsid core contains and protects viral RNA and enzymes ...

Lenacapavir works against the HIV-1 virus by inhibiting viral replication: it interferes with a number of essential steps of the viral lifecycle, including ...

Mechanism of Action. Capsid inhibitor. Lenacapavir is a long-acting, potent inhibitor of the HIV capsid protein with in vitro activity against viral strains ...

Due to the long half-life of lenacapavir following subcutaneous administration, SUNLENCA may increase the exposure of drugs primarily metabolized by CYP3A [see ...

Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat HIV/AIDS. It is taken by mouth or by subcutaneous injection.

The multi-stage mechanism of action of Sunlenca is distinguishable from other currently approved classes of antiviral agents and is designed to provide a new ...

Lenacapavir inhibits HIV-1 replication by interfering with multiple, essential steps of the viral lifecycle, including capsid-mediated nuclear uptake of HIV-1.

Lenacapavir is a first in class capsid inhibitor that exerts its inhibitory effect on HIV replication by binding to a structural protein of the capsid.

SUNLENCA received FDA breakthrough therapy designation and has a novel MOA that inhibits capsid function at multiple stages of the HIV-1 lifecycle. Watch a ... SUNLENCA Dosing · Subcutaneous Injection · First-in-Class MOA · Acquisition